These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38552905)

  • 21. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.
    Gupta AK; Talukder M; Williams G
    J Dermatolog Treat; 2022 Nov; 33(7):2946-2962. PubMed ID: 35920739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.
    Antoniou T; Macdonald EM; Yao Z; Gomes T; Tadrous M; Ho JM; Mamdani MM; Juurlink DN;
    BMC Musculoskelet Disord; 2018 May; 19(1):160. PubMed ID: 29789004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistent sexual side effects of finasteride: could they be permanent?
    Canguven O; Talib RA
    J Sex Med; 2013 May; 10(5):1441. PubMed ID: 23421328
    [No Abstract]   [Full Text] [Related]  

  • 24. Persistent sexual side effects of finasteride: could they be permanent?
    Irwig MS
    J Sex Med; 2012 Nov; 9(11):2927-32. PubMed ID: 22789024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Finasteride 1 mg in alopecia: sexual dysfunction, suicidal ideation. Providing balanced information to male patients is key.
    Prescrire Int; 2016 Oct; 25(175):242. PubMed ID: 30688421
    [No Abstract]   [Full Text] [Related]  

  • 26. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
    Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
    BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5-year data demonstrating clinical improvement with sustained efficacy.
    Choi S; Kwon SH; Sim WY; Lew BL
    J Dermatol; 2024 May; 51(5):684-690. PubMed ID: 38321615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guidelines on the use of finasteride in androgenetic alopecia.
    Mysore V; Shashikumar BM
    Indian J Dermatol Venereol Leprol; 2016; 82(2):128-34. PubMed ID: 26924401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis.
    Gupta AK; Mays RR; Dotzert MS; Versteeg SG; Shear NH; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2112-2125. PubMed ID: 29797431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mesotherapy with dutasteride for androgenetic alopecia: a concise review of the literature.
    Rodríguez-Cuadrado FJ; Pinto-Pulido EL; Fernández-Parrado M
    Eur J Dermatol; 2023 Feb; 33(1):72. PubMed ID: 37178048
    [No Abstract]   [Full Text] [Related]  

  • 31. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs.
    Pirozzi Farina F; Pischedda A
    Arch Ital Urol Androl; 2016 Jan; 87(4):312-6. PubMed ID: 26766804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients.
    Chung HC; Lee S; Lee WS
    J Dermatol; 2017 Dec; 44(12):1408-1409. PubMed ID: 27988928
    [No Abstract]   [Full Text] [Related]  

  • 33. Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia.
    Tsai TF; Choi GS; Kim BJ; Kim MB; Ng CF; Kochhar P; Jasper S; Brotherton B; Orban B; Lulic Z
    J Dermatol; 2018 Jul; 45(7):799-804. PubMed ID: 29667763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-finasteride syndrome: a surmountable challenge for clinicians.
    Traish AM
    Fertil Steril; 2020 Jan; 113(1):21-50. PubMed ID: 32033719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-alpha-reductase inhibitor treatment for frontal fibrosing alopecia: an evidence-based treatment update.
    Murad A; Bergfeld W
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1385-1390. PubMed ID: 29524253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
    Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
    J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms.
    Ganzer CA; Jacobs AR; Iqbal F
    Am J Mens Health; 2015 May; 9(3):222-8. PubMed ID: 24928450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistent Sexual Dysfunction with Finasteride 1 mg Taken for Hair Loss.
    Guo M; Heran B; Flannigan R; Kezouh A; Etminan M
    Pharmacotherapy; 2016 Nov; 36(11):1180-1184. PubMed ID: 27644029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System.
    Gupta AK; Carviel J; Gupta MA; Shear NH
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1373-1376. PubMed ID: 29194783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.